Evidence map›Paper›PMID 30174507›Full record

ArticleSaudi journal of biological sciences2018

The naturally occurring xanthone α-mangostin induces ROS-mediated cytotoxicity in non-small scale lung cancer cells.

Chunyun Zhang, Guifang Yu, Yifeng Shen

Open access · hybridAbstract read
In one paragraph

Article in Saudi journal of biological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
9.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Newly designed nanoparticle-drug delivery systems againstInternational journal of clinical and experimental pathology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Efficacy of Phytochemicals Derived from Roots ofMolecules (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. RETRACTED: Chamazulene-RichPlants (Basel, Switzerland) · 2020
    Article
  15. Article
  16. Nanoparticle Drug Delivery Systems for α-Mangostin.Nanotechnology, science and applications · 2020
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chunyun ZhangDepartment of Respiration, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.
Guifang YuDepartment of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.
Yifeng ShenGuangzhou Wondfo Biotech Co., Ltd, Guangzhou 510663, China.
Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (NSCLC) accounts for 85% of total deaths globally, and recent studies indicate the increasing risks of NSCLC in China and South Asian countries. Hence, development of new therapeutics against NSCLC has been a major concern. α-Mangostin, a naturally occurring xanthone, found abundantly in pericarps of mangosteen fruit is well known for its medicinal importance. The anticancer properties of α-mangostin against several types of cancer are also well documented. But the mechanism of action of α-mangostin against lung cancer is not well understood and requires further investigation. Therefore in the present study, we explored the therapeutic potential of α-mangostin against A549 cells. Treatment of A549 cells with α-mangostin resulted in a dose-dependent loss of cell viability, while the non-malignant cells such as

Indexed as

ApoptosisNSCLCROSα-Mangostin

Identifiers

PMID30174507
PMCPMC6116860
OpenAlexW2602017356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.